TRIAL RESULTS · SIDE EFFECTS
Cetrorelix side effects
ANSWER
In 2 placebo-controlled trials with posted results, the most common side effects of Cetrorelix were nasopharyngitis 8.9% (placebo 8.7%), injection site pain 8.5% (placebo 3.7%), headache 7.3% (placebo 7.3%). Read from ClinicalTrials.gov on 2026-10-03. Not medical advice.
Trial register
Trials with posted results
7
with an arm on Cetrorelix, of 140 registered
Against placebo
2
placebo-controlled trials
People in those trials
661
on Cetrorelix · 426 on placebo
Read
2026-10-03
ClinicalTrials.gov
VS PLACEBO
Most common side effects, Cetrorelix beside placebo
Share of people with each side effect in 2 placebo-controlled trials with posted results: 661 people on Cetrorelix (all doses), 426 on placebo, same trials. Listed only when reported for at least half of the people on Cetrorelix. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
ALL TRIALS
The 100 most reported of 127 side effects reported
Every trial with posted results and an arm on Cetrorelix (n ≥ 20), all phases, by people affected. Placebo is shown where placebo-controlled trials reported the same event. Comparator arms are not counted.
| Side effect | Organ system | Cetrorelix | Placebo | Trials |
|---|---|---|---|---|
| Headache | Nervous system disorders | 9.5% (62 of 653) | 7.3% | 2 |
| Hot flush | Vascular disorders | 9.3% (49 of 528) | - | 1 |
| Nasopharyngitis | Infections and infestations | 8.9% (40 of 449) | 8.7% | 1 |
| Injection site pain | General disorders | 8.5% (38 of 449) | 3.7% | 1 |
| Upper respiratory infection | Infections and infestations | 6.9% (31 of 449) | 6.0% | 1 |
| Back pain | Musculoskeletal and connective tissue disorders | 6.2% (28 of 449) | 6.4% | 1 |
| Diarrhea | Gastrointestinal disorders | 6.0% (27 of 449) | 2.8% | 1 |
| Musculoskeletal pain | Musculoskeletal and connective tissue disorders | 6.0% (27 of 449) | 2.8% | 1 |
| PSA increased | Investigations | 5.6% (25 of 449) | 2.3% | 1 |
| Hypertension | Vascular disorders | 4.7% (21 of 449) | 5.5% | 1 |
| Arthralgia | Skin and subcutaneous tissue disorders | 4.2% (19 of 449) | 4.6% | 1 |
| Dizziness | Nervous system disorders | 4.2% (19 of 449) | 5.0% | 1 |
| Hot flushes | Vascular disorders | 4.2% (19 of 449) | 2.8% | 1 |
| Rash | Skin and subcutaneous tissue disorders | 4.0% (18 of 449) | 2.8% | 1 |
| Sinusitis | Infections and infestations | 3.3% (15 of 449) | 0.9% | 1 |
| Cough | Respiratory, thoracic and mediastinal disorders | 2.9% (13 of 449) | 2.3% | 1 |
| Procedural pain | Injury, poisoning and procedural complications | 5.9% (12 of 204) | - | 1 |
| Erectile dysfunction | Respiratory, thoracic and mediastinal disorders | 2.4% (11 of 449) | 3.7% | 1 |
| Myalgia | Musculoskeletal and connective tissue disorders | 2.4% (11 of 449) | 0.5% | 1 |
| Prostatitis | Reproductive system and breast disorders | 2.4% (11 of 449) | 0.5% | 1 |
| Urinary tract infection | Infections and infestations | 2.4% (11 of 449) | 4.1% | 1 |
| Biochemical pregnancy | Pregnancy, puerperium and perinatal conditions | 5.4% (11 of 204) | - | 1 |
| Pelvic pain | Reproductive system and breast disorders | 5.4% (11 of 204) | - | 1 |
| Ovarian hyperstimulation syndrome | Reproductive system and breast disorders | 5.4% (11 of 204) | - | 1 |
| Fatigue | General disorders | 2.2% (10 of 449) | 4.6% | 1 |
| Libido decreased | Psychiatric disorders | 2.2% (10 of 449) | 2.3% | 1 |
| Influenza | Infections and infestations | 4.7% (10 of 212) | 5.3% | 1 |
| Nausea | Gastrointestinal disorders | 2.0% (9 of 449) | 4.1% | 1 |
| Oedema peripheral | General disorders | 2.0% (9 of 449) | 3.2% | 1 |
| Pain in extremity | Musculoskeletal and connective tissue disorders | 2.0% (9 of 449) | 2.3% | 1 |
| Pruritus | Skin and subcutaneous tissue disorders | 2.0% (9 of 449) | 1.4% | 1 |
| Urinary retention | Renal and urinary disorders | 2.0% (9 of 449) | 0.9% | 1 |
| Hypecholesterolemia | Metabolism and nutrition disorders | 1.8% (8 of 449) | 0.9% | 1 |
| Asthenia | General disorders | 1.6% (7 of 449) | 0.9% | 1 |
| coronary artery disease | Cardiac disorders | 0.6% (6 of 977) | 0.0% | 2 |
| ALT increased | Investigations | 1.3% (6 of 449) | 0.5% | 1 |
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | 0.9% (4 of 449) | 3.2% | 1 |
| prostate cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0.9% (4 of 449) | 0.9% | 1 |
| Inguinal hernia | Gastrointestinal disorders | 0.7% (3 of 449) | 2.3% | 1 |
| chest pain | General disorders | 0.2% (2 of 977) | 0.0% | 2 |
| angina pectoris | Cardiac disorders | 0.4% (2 of 449) | 0.0% | 1 |
| small intestinal obstruction | Gastrointestinal disorders | 0.1% (1 of 977) | 0.5% | 2 |
| IIIrd nerve paresis | Nervous system disorders | 0.2% (1 of 449) | 0.0% | 1 |
| asthma | Respiratory, thoracic and mediastinal disorders | 0.2% (1 of 449) | 0.0% | 1 |
| atrial fibrillation | Cardiac disorders | 0.2% (1 of 449) | 0.0% | 1 |
| bladder cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0.2% (1 of 449) | 0.0% | 1 |
| blood bilirubin increased | Investigations | 0.2% (1 of 449) | 0.0% | 1 |
| carbon monoxide poisoning | Injury, poisoning and procedural complications | 0.2% (1 of 449) | 0.0% | 1 |
| gastrointestinal carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0.2% (1 of 449) | 0.0% | 1 |
| grand mal convulsion | Nervous system disorders | 0.2% (1 of 449) | 0.0% | 1 |
| haematoma | Vascular disorders | 0.2% (1 of 449) | 0.0% | 1 |
| hypertensive emergency | Vascular disorders | 0.2% (1 of 449) | 0.0% | 1 |
| implant site infection | Infections and infestations | 0.2% (1 of 449) | 0.0% | 1 |
| joint dislocation | Injury, poisoning and procedural complications | 0.2% (1 of 449) | 0.0% | 1 |
| meningioma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0.2% (1 of 449) | 0.0% | 1 |
| myocardial infarction | Cardiac disorders | 0.2% (1 of 449) | 0.0% | 1 |
| osteoarthritis | Musculoskeletal and connective tissue disorders | 0.2% (1 of 449) | 0.0% | 1 |
| palpitations | Cardiac disorders | 0.2% (1 of 449) | 0.0% | 1 |
| pancreatitis | Gastrointestinal disorders | 0.2% (1 of 449) | 0.0% | 1 |
| pericarditis | Cardiac disorders | 0.2% (1 of 449) | 0.0% | 1 |
| post procedural haemorrhage | Injury, poisoning and procedural complications | 0.2% (1 of 449) | 0.0% | 1 |
| prostatitis | Reproductive system and breast disorders | 0.2% (1 of 449) | 0.0% | 1 |
| rash | Skin and subcutaneous tissue disorders | 0.2% (1 of 449) | 0.0% | 1 |
| rotator cuff syndrome | Musculoskeletal and connective tissue disorders | 0.2% (1 of 449) | 0.0% | 1 |
| syncope | Nervous system disorders | 0.2% (1 of 449) | 0.0% | 1 |
| urinary tract infection | Infections and infestations | 0.2% (1 of 449) | 0.0% | 1 |
| vocal cord paralysis | Nervous system disorders | 0.2% (1 of 449) | 0.0% | 1 |
| Cystitis haemorrhagic | Renal and urinary disorders | 0.5% (1 of 212) | 0.0% | 1 |
| Gastric cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0.5% (1 of 212) | 0.0% | 1 |
| Glaucoma | Eye disorders | 0.5% (1 of 212) | 0.0% | 1 |
| Herpes zoster ophtalmic | Infections and infestations | 0.5% (1 of 212) | 0.0% | 1 |
| Intermittent claudication | Vascular disorders | 0.5% (1 of 212) | 0.0% | 1 |
| Non-Hodgkin's lymphoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0.5% (1 of 212) | 0.0% | 1 |
| Osteoarthritis | Musculoskeletal and connective tissue disorders | 0.5% (1 of 212) | 0.0% | 1 |
| Spondylolisthesis | Musculoskeletal and connective tissue disorders | 0.5% (1 of 212) | 0.0% | 1 |
| Subileus | Gastrointestinal disorders | 0.5% (1 of 212) | 0.0% | 1 |
| Transient ischemic attack | Nervous system disorders | 0.5% (1 of 212) | 0.0% | 1 |
| appendicitis | Infections and infestations | 0.2% (1 of 528) | - | 1 |
| substance abuse | Psychiatric disorders | 0.2% (1 of 528) | - | 1 |
| hemorrhagic stroke | Vascular disorders | 0.2% (1 of 528) | - | 1 |
| rectal abcess | Infections and infestations | 0.2% (1 of 528) | - | 1 |
| humerus fracture | Injury, poisoning and procedural complications | 0.2% (1 of 528) | - | 1 |
| bladder transitional cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0.2% (1 of 528) | - | 1 |
| chest discomfort | Cardiac disorders | 0.2% (1 of 528) | - | 1 |
| chest pain / elevated cardiac enzymes | Cardiac disorders | 0.2% (1 of 528) | - | 1 |
| peripheral artery anuerysm / aortic aneurysm | Vascular disorders | 0.2% (1 of 528) | - | 1 |
| Hyperemesis gravidarum | Pregnancy, puerperium and perinatal conditions | 0.5% (1 of 204) | - | 1 |
| Adnexal torsion | Reproductive system and breast disorders | 0.5% (1 of 204) | - | 1 |
| Gastrooesophageal reflux disease | Gastrointestinal disorders | 0.0% (0 of 449) | 2.8% | 1 |
| abdominal wall abscess | Infections and infestations | 0.0% (0 of 449) | 0.5% | 1 |
| asthenia | General disorders | 0.0% (0 of 449) | 0.5% | 1 |
| atrial flutter | Cardiac disorders | 0.0% (0 of 449) | 0.5% | 1 |
| bursitis | Musculoskeletal and connective tissue disorders | 0.0% (0 of 449) | 0.5% | 1 |
| cellulitis of legs | Infections and infestations | 0.0% (0 of 449) | 0.5% | 1 |
| cerebrovascular accident | Nervous system disorders | 0.0% (0 of 449) | 0.9% | 1 |
| cholecystitis | Hepatobiliary disorders | 0.0% (0 of 449) | 0.5% | 1 |
| cholecystitis acute | Hepatobiliary disorders | 0.0% (0 of 449) | 0.5% | 1 |
| cholelithiasis | Hepatobiliary disorders | 0.0% (0 of 449) | 0.9% | 1 |
| decubitus ulcer | Skin and subcutaneous tissue disorders | 0.0% (0 of 449) | 0.5% | 1 |
| dehydration | Metabolism and nutrition disorders | 0.0% (0 of 449) | 0.5% | 1 |
Source: ClinicalTrials.gov posted results, read 2026-10-03. A trial lists events above its own reporting threshold, so a rare event may be missing from some trials. Not medical advice.
QUESTIONS
Does cetrorelix cause nasopharyngitis?
In 2 placebo-controlled trials with posted results, 8.9% of people on cetrorelix reported nasopharyngitis, against 8.7% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does cetrorelix cause injection site pain?
In 2 placebo-controlled trials with posted results, 8.5% of people on cetrorelix reported injection site pain, against 3.7% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does cetrorelix cause headache?
In 2 placebo-controlled trials with posted results, 7.3% of people on cetrorelix reported headache, against 7.3% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does cetrorelix cause upper respiratory infection?
In 2 placebo-controlled trials with posted results, 6.9% of people on cetrorelix reported upper respiratory infection, against 6.0% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does cetrorelix cause back pain?
In 2 placebo-controlled trials with posted results, 6.2% of people on cetrorelix reported back pain, against 6.4% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
REGISTERED STUDIES
140 registered clinical trials of Cetrorelix
The 10 most recently updated are listed.
| NCT07732348 | Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist in Controlled Ovarian Stimulation for In Vitro Fertilization: A Randomized Controlled Non-Inferiority Trial With a Concurrent Comparator Cohort Undergoing Progestin-Primed Ovarian Stimulation (PPOS) Status: NOT_YET_RECRUITING · Updated 2026-09-30 |
|---|---|
| NCT07836400 | Half-dose vs Conventional-dose Cetrorelix in ICSI Cycles Status: NOT_YET_RECRUITING · Updated 2026-09-23 |
| NCT07340827 | A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) Status: RECRUITING · Updated 2026-09-08 |
| NCT07736261 | Drospirenone-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing Freeze-All IVF/ICSI Status: NOT_YET_RECRUITING · Updated 2026-07-30 |
| NCT06572930 | Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation Status: RECRUITING · Updated 2026-06-25 |
| NCT06212102 | Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation Status: RECRUITING · Updated 2026-05-04 |
| NCT05951400 | Progesterone Primed Protocol Versus GnRH Antagonist in With PCO Undergoing ICSI Status: COMPLETED · Updated 2026-04-15 |
| NCT02892942 | NATural Ovarian Stimulation Status: COMPLETED · Updated 2026-04-03 |
| NCT02890082 | Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer Status: ACTIVE_NOT_RECRUITING · Updated 2026-03-31 |
| NCT04719000 | PErsonalized Addition of Recombinant LH in Ovarian Stimulation Status: RECRUITING · Updated 2026-03-30 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.